|
||
| |||||||
|
Synco Biopartners And Cobra Biomanufacturing Form Alliance To Manufacture Plasmid Dna For Phase III Trials And Commercial Supply
Keele, UK, 4th May
2005 – SynCo
Bio Partners B.V., a leading, contract manufacturing organization and Keele,
UK, Cobra Biomanufacturing Plc (AIM:CBF.L), the international manufacturer of
biopharmaceuticals, announce they have formed an alliance to manufacture
plasmid DNA for Phase III trials and commercial supply.
Under the terms of the agreement, SynCo has acquired the
license to Cobra’s intellectual property rights in the pDNA manufacturing
process. This will enable SynCo to manufacture pDNA for both Phase III studies
and for commercial supply. Cobra will continue to offer preclinical, Phase I
and Phase II pDNA manufacture.
SynCo and Cobra have also agreed to collaborate in the
marketing of their pDNA manufacturing services and to collaborate in providing
a first class, integrated service to potential customers.
David Thatcher, Chief Executive, Cobra Biomanufacturing
said: ”Cobra is proud to form this important alliance with SynCo Bio Partners
B.V., SynCo is a leading manufacturer with a licensed facility and an
impressive track record in the production of large-scale recombinant
biopharmaceuticals and vaccines for clinical trials and market supply. SynCo
has immense manufacturing strengths, which truly complement Cobra’s
capabilities in development and IP, making them an ideal partner.”
Pierre Warffemius, CEO of SynCo Bio Partners B.V. added:
“This agreement leverages our position as a leading CMO in the
biopharmaceutical market. We look forward to a very productive collaboration
with Cobra, a recognized leader in the plasmid DNA market with an impressive
IP portfolio. I believe there are great synergies between their expertise in
pDNA and our specialist, large-scale manufacturing capabilities and I look
forward to offering customers a first class service”.
-Ends-
For further details, please contact:
David Thatcher, Chief Executive Officer
Cobra Biomanufacturing Tel: + 44 (0) 1782 714181
Mark Court/Rebecca Skye Dietrich
Buchanan Communications Tel:+ 44 (0) 207 466 5000
Eileen Paul
Northbank Communications Tel:+ 44 (0) 1260 296500 Notes to Editors:
Cobra Biomanufacturing Plc
Cobra Biomanufacturing Plc is a leading international manufacturer of biopharmaceuticals to the lifescience industry. Founded in 1992, Cobra provides innovative manufacturing solutions to the biopharmaceutical industry covering DNA, virus, cellular therapeutics and recombinant protein products.
Cobra was the first company to develop and gain GMP (Good
Manufacturing Practice) standard DNA manufacture in Europe, with specific
expertise in DNA medicines. A range of unique, patented technologies,
underpins this revenue generating business.
Cobra floated on the Alternative Investment Market of the
London Stock Exchange in June 2002 raising £7 million and raised a further
£5.2 million in May 2003 in order to further expand capacity in Oxford UK.
Cobra is committed to conducting its manufacturing
activities in accordance with appropriate current Good Manufacturing
Practice (cGMP) and Good Control Laboratory Practice (GCLP) regulations
and/or guidelines. The MHRA has granted a “Manufacturer’s Authorization for
Investigational Medicinal Products” under the Directive 2001/20/EC and
applies to booth the Keele and Oxford facilities. The designated site
numbers are: Keele #11618 and Oxford #12486.
SynCo Bio Partners B.V
SynCo Bio Partners B.V. is focused on the manufacture and
development of biopharmaceuticals and has a track record of expertise in the
production of recombinant proteins and vaccines. SynCo Bio Partners B.V.
offers a fully integrated range of services in manufacturing and supports
biopharmaceutical companies from the earliest stage in process development,
through clinical trials to market supply. Established in 2000 and privately
owned, SynCo collaborates with a number of leading biopharmaceutical
companies, in Europe and the USA. Approximately 100 employees are based at the
company’s headquarters and manufacturing facility in Amsterdam, NL. Here,
SynCo’s activities include analytical and process development for new
products, manufacture of Active Pharmaceutical Ingredients for licensed
products and clinical trials, and aseptic filling and lyophilization (for
clinical trials and market supply).
|
|
| ||||||||